Novavax Inc (NASDAQ:NVAX) — Market Cap & Net Worth
Market Cap & Net Worth: Novavax Inc (NVAX)
Novavax Inc (NASDAQ:NVAX) has a market capitalization of $1.31 Billion ($1.31 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7746 globally and #2312 in its home market, demonstrating a -8.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novavax Inc's stock price $9.35 by its total outstanding shares 164945726 (164.95 Million). Also see Novavax Inc assets under control for a full breakdown of the balance sheet.
Novavax Inc Market Cap History: 2015 to 2026
Novavax Inc's market capitalization history from 2015 to 2026. Data shows change from $27.68 Billion to $1.54 Billion (-22.48% CAGR). Also see Novavax Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Novavax Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.11% | #20 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.05% | #225 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #854 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.07% | #132 of 263 |
Weight: Novavax Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novavax Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novavax Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NVAX stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.99x
Novavax Inc's market cap is 0.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.52x
Novavax Inc's market cap is 2.52 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.16 Billion | $15.35 Million | -$279.97 Million | 270.74x | N/A |
| 2017 | $4.09 Billion | $31.18 Million | -$183.77 Million | 131.21x | N/A |
| 2018 | $6.07 Billion | $34.29 Million | -$184.75 Million | 177.03x | N/A |
| 2019 | $656.48 Million | $18.66 Million | -$130.10 Million | 35.18x | N/A |
| 2020 | $18.39 Billion | $475.60 Million | -$427.50 Million | 38.67x | N/A |
| 2021 | $23.60 Billion | $1.15 Billion | -$1.74 Billion | 20.59x | N/A |
| 2022 | $1.70 Billion | $1.60 Billion | -$657.94 Million | 1.06x | N/A |
| 2023 | $791.74 Million | $556.38 Million | -$545.06 Million | 1.42x | N/A |
| 2024 | $1.33 Billion | $682.16 Million | -$187.50 Million | 1.94x | N/A |
| 2025 | $1.11 Billion | $1.12 Billion | $440.30 Million | 0.99x | 2.52x |
Competitor Companies of NVAX by Market Capitalization
Companies near Novavax Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Novavax Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Novavax Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Novavax Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Novavax Inc's market cap moved from $27.68 Billion to $ 1.54 Billion, with a yearly change of -22.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.54 Billion | +39.14% |
| 2025 | $1.11 Billion | -16.42% |
| 2024 | $1.33 Billion | +67.50% |
| 2023 | $791.74 Million | -53.31% |
| 2022 | $1.70 Billion | -92.81% |
| 2021 | $23.60 Billion | +28.30% |
| 2020 | $18.39 Billion | +2701.76% |
| 2019 | $656.48 Million | -89.18% |
| 2018 | $6.07 Billion | +48.39% |
| 2017 | $4.09 Billion | -1.59% |
| 2016 | $4.16 Billion | -84.98% |
| 2015 | $27.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Novavax Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.31 Billion USD |
| MoneyControl | $1.31 Billion USD |
| MarketWatch | $1.31 Billion USD |
| marketcap.company | $1.31 Billion USD |
| Reuters | $1.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more